Physician profile
Amanda P Wakim
NPI 1245536408
$169,471.48
in general payments reported to CMS, 2019-2025
15 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $16K · 2023: $70K · 2024: $46K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Travel and Lodging: $5,292 · Food and Beverage: $5,244 · Consulting Fee: $3,150 · Education: $272 · Gift: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,090.24 |
| Travel and Lodging | $5,292.27 |
| Food and Beverage | $5,244.27 |
| Consulting Fee | $3,150.00 |
| Education | $272.05 |
| Gift | $178.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $133,325.51 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $27,432.64 | 2021-2025 | |
| Zealand Pharma US, INC. | $2,711.93 | 2021-2022 | |
| Corcept Therapeutics | $1,524.36 | 2024-2025 | Korlym |
| Novo Nordisk INC | $1,512.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,340.40 | 2022-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $619.82 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $244.65 | 2023-2025 | Repatha, Evenity, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.71 | 2022-2023 | Jardiance |
| Lilly USA, LLC | $152.71 | 2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $123.38 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $109.04 | 2021 | |
| Inspire Medical Systems, INC. | $108.52 | 2023 | Inspire |
| Averitas Pharma INC. | $74.47 | 2024 | Qutenza |
| Abbott Laboratories | $22.00 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.